Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836880 plus ezabenlimab dose-finding study in advanced solid tumors
jRCT2031200207Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of BI 836880 and ezabenlimab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: Shrinkage estimator of objective response based on BHM. Started Mar 2021; status: completed.
02
Drugs
BI 836880ezabenlimab
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200207.